Antiviral drug vidarabine possessing cardiac type 5 adenylyl cyclase inhibitory property did not affect cardiohemodynamic or electrophysiological variables in the halothane-anesthetized dogs

The Journal of Toxicological Sciences
Takeshi WadaA Sugiyama

Abstract

Vidarabine has been used for the treatment of patients with local and systemic herpes virus infection; moreover, it was recently reported that it inhibits cardiac type 5 adenylyl cyclase. Furthermore, vidarabine has been shown to suppress atrial fibrillation and improve congestive heart failure in experimental models of mice induced by the isoproterenol infusion. Since information that can explain its experimentally demonstrated efficacy against congestive heart failure and atrial fibrillation remains limited, in this study we precisely assessed cardio-electropharmacological effect using the halothane-anesthetized canine model. Vidarabine was intravenously administrated in three escalating doses of 1, 10, 100 mg/kg over 10 min with a pause between the doses (n = 4). Meanwhile, the vehicle dimethyl sulfoxide in volumes of 0.033, 0.033 and 0.33 mL/kg was intravenously administrated in the same manner as was vidarabine (n = 4). No significant difference was detected in any cardiohemodynamic or electrophysiological variables between the vehicle- and vidarabine-treated groups, which indicates that effective doses of vidarabine adequately inhibiting type 5 adenylyl cyclase did not affect the cardiovascular variables in vivo at all, s...Continue Reading

References

Nov 1, 1989·Journal of Pharmacological Methods·A Van de WaterR S Reneman
Sep 13, 2002·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroshi YoshidaKeitaro Hashimoto
Jul 21, 2004·The Journal of Biological Chemistry·Kousaku IwatsuboYoshihiro Ishikawa
May 27, 2008·Circulation Journal : Official Journal of the Japanese Circulation Society·Tomomichi IshizakaAtsushi Sugiyama
Jul 24, 2010·British Journal of Pharmacology·J C McGrathC L Wainwright
Jul 24, 2010·British Journal of Pharmacology·Carol KilkennyUNKNOWN NC3Rs Reporting Guidelines Working Group
Aug 4, 2010·Cardiovascular Toxicology·Yoshitaka MitsumoriAtsushi Sugiyama
Dec 2, 2010·Advances in Experimental Medicine and Biology·Clara Thompson, Richard Whitley
Mar 20, 2012·Osteoarthritis and Cartilage·C KilkennyD G Altman
Apr 17, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Kosaku IwatsuboYoshihiro Ishikawa
Jan 7, 2015·The Journal of Toxicological Sciences·Yukiko Yamazaki-HashimotoAtsushi Sugiyama

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.